Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 5/20 | 0.41 |
| ▸ | PGR | P06401 | 8/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986440 | 0.68 | HTR2A (0.45) | ELOVL6PGRNR3C1NR3C2AR | |
| SCHEMBL6986545 | 0.68 | CYP46A1 (0.44) | ELOVL6PGRNR3C1NR3C2AR | |
| SCHEMBL2260381 | 0.62 | PGR (0.49) | PGRNR3C1NR3C2ARADRA2C | |
| SCHEMBL12394684 | 0.61 | PGR (0.71) | ELOVL6PGRNR3C1NR3C2AR | |
| SCHEMBL4120633 | 0.56 | ELOVL6 (0.42) | ELOVL6PGR | |
| SCHEMBL31727513 | 0.56 | HTR6 (0.41) | PGRADRA2CTACR2ADRA1DHTR2A | |
| SCHEMBL4586111 | 0.56 | CES1 (0.52) | — | |
| SCHEMBL5516094 | 0.55 | LMNA (0.42) | ELOVL6PGRNR3C1NR3C2AR | |
| SCHEMBL5115070 | 0.55 | PGR (0.47) | PGRNR3C1NR3C2AR | |
| SCHEMBL3870838 | 0.54 | PGR (0.78) | PGRNR3C1NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428049-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190016701-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428049-B2 | TRPA1 modulators | TRPA1, TRPV1, TRPV2 | ELOVL6 1047/4885PGR 3776/4885NR3C1 1716/4885 |
| US-20190016701-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | ELOVL6 1047/4885PGR 3776/4885NR3C1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.